View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 7, 2011

Sanofi submits marketing authorisation application for Lyxumia drug

Danish biopharmaceutical firm Zealand Pharma has announced that its partner Sanofi has submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe.

Danish biopharmaceutical firm Zealand Pharma has announced that its partner Sanofi has submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe.

Lixisenatide, developed by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for type 2 diabetes.

Sanofi is set to complete the Phase III development of the drug as a new treatment for the disease.

The marketing authorisation application includes data from the GetGoal Phase III programme, comprising nine studies involving over 4,300 patients.

The trial is intended to provide data for supporting lixisenatide as a treatment for type 2 diabetes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena